While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

GSK (LON: GSK) has issued an update which inevitably reflects the difficulties faced in the last year, while also providing a host of reasons to be more upbeat on future prospects. Concerns over the ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

GSK has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a 4% rise ...

GSK’s lead in vaccines is a cause for concern after mixed political signals in the US, with ardent vaccine sceptic Robert F Kennedy Jr vowing a clampdown on the pharmaceutical industry, which partly ...

The Shanghai Composite fell 0.7% in afternoon trade. It was the first time the Shanghai market re-opened after the Chinese New Year break. The Hang Seng Index in Hong Kong was down 0.9%. Tokyo's ...